Compare Stocks: BIVI, XBIT, XLO, and GOSS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIVI BioVie	$1.73 +26.3%	$1.62	$0.82 ▼ $3.79	$11.90M	0.78	173,852 shs	13.31 million shs
GOSS Gossamer Bio	$9.28 -1.8%	$11.11	$8.29 ▼ $309.60	$56.71M	2.28	216,712 shs	139,417 shs
XBIT XBiotech	$1.99 +3.6%	$2.14	$1.80 ▼ $3.44	$58.54M	0.76	93,434 shs	132,747 shs
XLO Xilio Therapeutics	$8.68 +8.6%	$8.78	$6.47 ▼ $12.04	$52.58M	-0.13	15,037 shs	24,452 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIVI BioVie	+26.28%	+20.14%	+18.49%	-15.20%	+1.17%
GOSS Gossamer Bio	-1.80%	-5.02%	-13.35%	-34.72%	-95.15%
XBIT XBiotech	+3.65%	+7.57%	-9.13%	-11.95%	-13.10%
XLO Xilio Therapeutics	+8.23%	+8.36%	-3.66%	-4.72%	-27.05%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIVI BioVie	$1.73 +26.3%	$1.62	$0.82 ▼ $3.79	$11.90M	0.78	173,852 shs	13.31 million shs
GOSS Gossamer Bio	$9.28 -1.8%	$11.11	$8.29 ▼ $309.60	$56.71M	2.28	216,712 shs	139,417 shs
XBIT XBiotech	$1.99 +3.6%	$2.14	$1.80 ▼ $3.44	$58.54M	0.76	93,434 shs	132,747 shs
XLO Xilio Therapeutics	$8.68 +8.6%	$8.78	$6.47 ▼ $12.04	$52.58M	-0.13	15,037 shs	24,452 shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIVI BioVie	+26.28%	+20.14%	+18.49%	-15.20%	+1.17%
GOSS Gossamer Bio	-1.80%	-5.02%	-13.35%	-34.72%	-95.15%
XBIT XBiotech	+3.65%	+7.57%	-9.13%	-11.95%	-13.10%
XLO Xilio Therapeutics	+8.23%	+8.36%	-3.66%	-4.72%	-27.05%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIVI BioVie	1.00	Sell	N/A	N/A
GOSS Gossamer Bio	2.30	Hold	$256.00	2,658.62% Upside
XBIT XBiotech	1.00	Sell	N/A	N/A
XLO Xilio Therapeutics	2.00	Hold	$16.00	84.33% Upside

Current Analyst Ratings Breakdown

Latest BIVI, XBIT, XLO, and GOSS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/30/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/26/2026	GOSS Gossamer Bio	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
10/23/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/22/2026	XLO Xilio Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold
10/21/2026	XLO Xilio Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$16.00
10/16/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/15/2026	BIVI BioVie	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/13/2026	GOSS Gossamer Bio	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy
10/9/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/6/2026	XLO Xilio Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/28/2026	XBIT XBiotech	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIVI BioVie	N/A	N/A	N/A	N/A	$1.36 per share	N/A
GOSS Gossamer Bio	$53.29M	1.06	N/A	N/A	($42.43) per share	-0.22
XBIT XBiotech	N/A	N/A	N/A	N/A	$4.60 per share	N/A
XLO Xilio Therapeutics	$43.77M	1.30	N/A	N/A	$7.31 per share	1.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIVI BioVie	-$22.07M	-$3.15	N/A	N/A	N/A	N/A	-126.02%	-108.88%	11/9/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$56.00	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
XBIT XBiotech	-$45.54M	-$1.48	N/A	N/A	N/A	N/A	-31.62%	-30.29%	N/A
XLO Xilio Therapeutics	-$35.04M	-$1.64	N/A	N/A	N/A	-34.06%	-71.99%	-20.43%	11/12/2026 (Estimated)

Latest BIVI, XBIT, XLO, and GOSS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	XLO Xilio Therapeutics	-$0.9350	N/A	N/A	N/A	$4.92 million	N/A
11/4/2026	Q3 2026	GOSS Gossamer Bio	-$3.9340	N/A	N/A	N/A	$12.16 million	N/A
8/13/2026	Q2 2026	XBIT XBiotech	$0.03	-$0.22	-$0.25	-$0.22	$7.00 million	N/A
8/13/2026	Q2 2026	XLO Xilio Therapeutics	-$0.59	-$0.33	+$0.26	-$0.33	$12.72 million	$18.69 million
8/12/2026	Q4 2026	BIVI BioVie	-$0.52	-$0.70	-$0.18	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIVI BioVie	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
XBIT XBiotech	N/A	N/A	N/A	N/A	N/A
XLO Xilio Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIVI BioVie	N/A	3.59	3.59
GOSS Gossamer Bio	N/A	0.53	0.53
XBIT XBiotech	N/A	33.15	33.15
XLO Xilio Therapeutics	N/A	4.25	4.25

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIVI BioVie	4.59%
GOSS Gossamer Bio	81.23%
XBIT XBiotech	55.70%
XLO Xilio Therapeutics	54.29%

Insider Ownership

Company	Insider Ownership
BIVI BioVie	16.70%
GOSS Gossamer Bio	4.15%
XBIT XBiotech	21.10%
XLO Xilio Therapeutics	7.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIVI BioVie	13	8.68 million	7.23 million	No Data
GOSS Gossamer Bio	162	6.11 million	5.86 million	Optionable
XBIT XBiotech	87	30.49 million	24.06 million	Optionable
XLO Xilio Therapeutics	76	6.58 million	6.09 million	Not Optionable

BIVI, XBIT, XLO, and GOSS Headlines

Recent News About These Companies

Xilio Therapeutics (NASDAQ:XLO) Stock Price Breaks Above Two Hundred Day Moving Average - Here's Why

3 hours ago | americanbankingnews.com

Xilio Therapeutics (NASDAQ:XLO) Share Price Breaks Above 200-Day Moving Average - What's Next?

3 hours ago | marketbeat.com

Xilio Therapeutics to Present at the Stifel 2026 Healthcare Conference

November 3 at 4:30 PM | globenewswire.com

Xilio Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of XTX501 in Patients with Metastatic NSCLC

October 26, 2026 | globenewswire.com

Xilio Therapeutics (NASDAQ:XLO) Stock Rating Upgraded by Zacks Research

October 24, 2026 | marketbeat.com

Xilio Therapeutics (NASDAQ:XLO) Now Covered by Analysts at Raymond James Financial

October 21, 2026 | marketbeat.com

Xilio Therapeutics (NASDAQ:XLO) Stock Falls 1.2% - Here's What Happened

October 7, 2026 | marketbeat.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - October 2, 2026

October 5, 2026 | biospace.comB

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 2, 2026 | globenewswire.com

Xilio Names Yariv Houvras Chief Medical Officer

September 28, 2026 | rttnews.com

Xilio Therapeutics Appoints Yariv J. Houvras, M.D., Ph.D. as Chief Medical Officer

September 28, 2026 | markets.businessinsider.com

Xilio Therapeutics Appoints Yariv J. Houvras, M.D.

September 28, 2026 | globenewswire.com

Xilio Therapeutics Grants Inducement Stock Options to New Employees Under 2022 Plan

September 2, 2026 | quiverquant.comQ

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2026 | globenewswire.com

Xilio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Pipeline and Business Updates

August 12, 2026 | globenewswire.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | markets.businessinsider.com

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 6, 2026 | globenewswire.com

Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | finanznachrichten.de

Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer

June 29, 2026 | globenewswire.com

Xilio Therapeutics Inc

June 2, 2026 | edition.cnn.com

Cancer Stocks That Are Advancing the Future of Oncology Care

May 18, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI, XBIT, XLO, and GOSS Company Descriptions

BioVie NASDAQ:BIVI

$1.73 +0.36 (+26.28%)

Closing price 11/3/2026 04:00 PM Eastern

Extended Trading

$1.74 +0.02 (+0.87%)

As of 07:00 AM Eastern

BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.

Gossamer Bio NASDAQ:GOSS

$9.28 -0.17 (-1.80%)

Closing price 11/3/2026 04:00 PM Eastern

Extended Trading

$9.47 +0.19 (+2.08%)

As of 07:00 AM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

XBiotech NASDAQ:XBIT

$1.99 +0.07 (+3.65%)

Closing price 11/3/2026 04:00 PM Eastern

Extended Trading

$1.97 -0.02 (-1.01%)

As of 11/3/2026 07:30 PM Eastern

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Xilio Therapeutics NASDAQ:XLO

$8.68 +0.69 (+8.64%)

Closing price 11/3/2026 04:00 PM Eastern

Extended Trading

$8.75 +0.07 (+0.79%)

As of 05:48 AM Eastern

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIVI, XBIT, XLO, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIVI, XBIT, XLO, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIVI, XBIT, XLO, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI, XBIT, XLO, and GOSS Company Descriptions

BioVie NASDAQ:BIVI

Gossamer Bio NASDAQ:GOSS

XBiotech NASDAQ:XBIT

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BIVI, XBIT, XLO, and GOSS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BIVI, XBIT, XLO, and GOSS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BIVI, XBIT, XLO, and GOSS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BIVI, XBIT, XLO, and GOSS Company Descriptions

BioVie NASDAQ:BIVI

Gossamer Bio NASDAQ:GOSS

XBiotech NASDAQ:XBIT

Xilio Therapeutics NASDAQ:XLO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools